➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
McKinsey
McKesson
Moodys

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Elobixibat

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Elobixibat?

Elobixibat is an investigational drug.

There have been 7 clinical trials for Elobixibat. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Constipation, Non-alcoholic Fatty Liver Disease, and Liver Diseases. The leading clinical trial sponsors are Ferring Pharmaceuticals, Albireo, and Mayo Clinic.

There are thirty-one US patents protecting this investigational drug and six hundred and thirty-three international patents.

Recent Clinical Trials for Elobixibat
TitleSponsorPhase
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver DiseaseEA Pharma Co., Ltd.Phase 2
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver DiseaseYokohama City UniversityPhase 2
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASHAlbireoPhase 2

See all Elobixibat clinical trials

Clinical Trial Summary for Elobixibat

Top disease conditions for Elobixibat
Top clinical trial sponsors for Elobixibat

See all Elobixibat clinical trials

US Patents for Elobixibat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Elobixibat   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Start Trial
Elobixibat   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Start Trial
Elobixibat   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (N/A)   Start Trial
Elobixibat   Start Trial Crystal modifications of elobixibat Elobix AB (Goteborg, SE)   Start Trial
Elobixibat   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Goteborg, SE)   Start Trial
Elobixibat   Start Trial Process for the preparation of 1,5-benzothiazepine compounds Elobix AB (Goteborg, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Elobixibat

Drugname Country Document Number Estimated Expiration Related US Patent
Elobixibat Australia AU2011326871 2030-11-08   Start Trial
Elobixibat Brazil BR112013010157 2030-11-08   Start Trial
Elobixibat Canada CA2815749 2030-11-08   Start Trial
Elobixibat China CN103260625 2030-11-08   Start Trial
Elobixibat China CN105288580 2030-11-08   Start Trial
Elobixibat Cyprus CY1118125 2030-11-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
McKinsey
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.